Eric Angevin

4PUBLICATIONS
53CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Feb 06, 2024
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.

Solange Peters, Eric Angevin, Teresa Alonso-Gordoa

|Jun 01, 2023
A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.

Melinda A Pruis, Matthew G Krebs, Ruth Plummer

|Oct 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.

Omid Hamid, Alberto A Chiappori, John A Thompson

|Oct 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.

D Ross Camidge, Fabrice Barlesi, Jonathan W Goldman

Pageof 1

Frequent Collaborators

1 joint publications

D Ross Camidge

1 joint publications

Jonathan W Goldman

1 joint publications

Daniel Morgensztern

1 joint publications

Rebecca Heist